Scandinavian Pharma Group ApS: Financial statements 2023
CVR: 42650668
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Scandinavian Pharma Group ApS (CVR 42650668) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -307,714 and a net result of DKK -246,639. Equity in the 2023 report amounted to DKK -218,716.
- Gross Profit
- DKK -307,714
- Profit/Loss
- DKK -246,639
- Equity
- DKK -218,716
- Total Assets
- DKK 241,400
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Scandinavian Pharma Group ApS has published its interim report for the period September 1, 2021 – December 31, 2022.
As of February 16, 2023, Helle Aakvist Jensen is registered as director of Scandinavian Pharma Group ApS.
As of February 16, 2023, Nick Hielscher Abel is registered as adm. dir. of Scandinavian Pharma Group ApS.
As of February 16, 2023, Camilla Rude Bromark is registered as director of Scandinavian Pharma Group ApS.
As of February 15, 2023, Nick Hielscher Abel has stepped down as director of Scandinavian Pharma Group ApS.
About Scandinavian Pharma Group ApS
Scandinavian Pharma Group ApS was a Danish company of the type Anpartsselskab based in København S, founded in 2021. The company has been dissolved on 10 April 2026. The company was registered under the industry Detailhandel med kosmetikvarer og toiletartikler. The company was previously named NG Leasing ApS. According to the 2023 annual report, the company had an average of 0 employees. In 2023, the company reported a gross profit of DKK -307,714 and a net result of DKK -246,639. Equity in the 2023 report amounted to DKK -218,716.